MJ Biz Daily reports..

Several major financial institutions have assigned stock analysts to follow GW Pharmaceuticals, which trades on the Nasdaq.

The list includes Bank of America Merrill Lynch, Morgan Stanley, Cowen and Company, Roth Capital Partners, Leerink Partners, and Piper Jaffray & Co.

Several other major financial institutions have increased their shares in the company as of late, including Bank of America, Deutsche Bank and Janus Capital Management, according to Financial-Market-News.com.

GW Pharma made waves earlier this month when it announced that its Epidiolex syrup reduced episodes of a rare and severe form of epilepsy, Dravet Syndrome, by 39% in a study group of children.

That means it also successfully passed Phase III Clinical Trials, the last hurdle a company needs to clear before it can request approval from the FDA to start selling the drug on the U.S. market.

The study results sent GW ‘s stock price soaring after several months of lackluster performance.

As recently as March 10, GW’s stock hit a 52-week low of $35.83.

After the results were announced on March 14, however, the stock jumped to $91.65, though it has retreated a bit since then to around $75 a share.

Full Report At

https://mjbizdaily.com/gw-pharma-success-increases-mmj-credibility/